Prospective and randomized study on the efficacy of novel hypoglycemic type 2 diabetes agent ipragliflozin to serum glycemic control and cardiovascular risk factors

INTERVENTION: Orally administration of 50 mg ipragliflozin once a day, pre or post breakfast for 12 weeks Ipragliflozin non‐administrated group (Continuation of conventional therapy) CONDITION: Type 2 diabetes PRIMARY OUTCOME: 1) Improving effects of sd‐LDL, IDL, LDL and HDL using by Lipofo‐AS; 2) TC, TG, HDL‐C, LDL‐C, LDL/HDL‐C rate and non HDL‐C SECONDARY OUTCOME: 1) Lowering effects of body weight and blood pressure; 2) Improving effects of hsCRP, HOMA‐beta and HOMA‐R; 3) Lowering effects of HbA1c and GA INCLUSION CRITERIA: 1) Aged from 20 to less than 65 years at providing consent 2) Type 2 diabetes patients with BMI >= 24 kg/m2 3) HbA1c (NGSP) was from 7% to less than 10% for 3 months or more, under conventional thrapy (HbA1c >= 7.5% in case of having sulfonylureas and glinides)